Detalles de la búsqueda
1.
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?
Haematologica
; 109(3): 888-894, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646655
2.
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Br J Haematol
; 188(6): 907-917, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31898319
3.
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Hematol Oncol
; 38(5): 754-762, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32950042
4.
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
Am J Hematol
; 95(7): 759-765, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32242970
5.
Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma.
Am J Hematol
; 98(9): E230-E232, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37317959
6.
Autologous transplantation and maintenance therapy in multiple myeloma.
N Engl J Med
; 371(10): 895-905, 2014 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-25184862
7.
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Blood
; 122(8): 1376-83, 2013 Aug 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-23775712
8.
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Blood
; 122(16): 2799-806, 2013 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-23954889
9.
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Blood
; 119(4): 933-9; quiz 1093, 2012 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-21835953
10.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Blood
; 120(1): 9-19, 2012 Jul 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22498745
11.
Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma.
Am J Hematol
; 87(2): 150-4, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22189759
12.
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Lancet
; 376(9758): 2075-85, 2010 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-21146205
13.
Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
Cancer Med
; 10(17): 5859-5865, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34263564
14.
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.
Leukemia
; 35(10): 2885-2894, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34079042
15.
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
Ann Hematol
; 89(2): 185-90, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19633847
16.
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Lancet Haematol
; 7(12): e861-e873, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33242443
17.
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
Haematologica
; 99(2): e14-6, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24497562
18.
Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome.
Leuk Lymphoma
; 60(12): 3044-3050, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31120311
19.
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.
J Cancer Res Clin Oncol
; 144(7): 1357-1366, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29675792
20.
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Haematologica
; 90(12): 1643-9, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16330437